GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
The DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Serum calcitonin (CT) is a well-accepted marker of C-cell proliferation, particularly in medullary thyroid carcinoma. Chronic glucagon-like peptide-1 (GLP-1) receptor agonist administration in rodents has been associated with increased serum CT levels and C-cell tumor formation. There are no longitudinal studies measuring CT in humans without medullary thyroid carcinoma or a family history of medullary thyroid carcinoma and no published studies on the effect of GLP-1 receptor agonists on human serum CT concentrations. AIM: The aim of the study was to determine serum CT response over time to the GLP-1 receptor agonist liraglutide in subjects with type 2 diabetes mellitus or nondiabetic obese subjects. METHODS: Unstimulated serum CT concentrations were measured at 3-month intervals for no more than 2 yr in a series of trials in over 5000 subjects receiving liraglutide or control therapy. RESULTS: Basal mean CT concentrations were at the low end of normal range in all treatment groups and remained low throughout the trials. At 2 yr, estimated geometric mean values were no greater than 1.0 ng/liter, well below upper normal ranges for males and females. Proportions of subjects whose CT levels increased above a clinically relevant cutoff of 20 ng/liter were very low in all groups. There was no consistent dose or time-dependent relationship and no consistent difference between treatment groups. CONCLUSIONS: These data do not support an effect of GLP-1 receptor activation on serum CT levels in humans and suggest that findings previously reported in rodents may not apply to humans. However, the long-term consequences of GLP-1 receptor agonist treatment are a subject of further studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [76]
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Self-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Self-citationZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citationon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Self-citationMarre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Self-citationBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Self-citationPratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“thyroid [855,856], and involvement of calcitonin in GLP-1-mediated osteoclast activation has been suspected [854].”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“Furthermore, the available clinical data from studies of diabetic or nondiabetic obese subjects receiving continuous treatment with liraglutide for up to 2 years do not reveal significant increases in calcitonin levels over time (Hegedüs et al., 2011).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Thyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
“In contrast, human C cells express a much lower level of GLP-1R protein, and follow-up of thousands of subjects treated with liraglutide for diabetes or obesity for several years has not detected an increase in plasma calcitonin in exposed subjects (218).”
BackgroundNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“In accordance with these observations, a 2-year clinical study could not demonstrate plasma calcitonin increases in patients treated with liraglutide [36], even in high doses used to treat obesity [75].”
BackgroundEfficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272
“Nevertheless, monkeys and humans exhibit major differences in GLP-1R expression in their thyroid C-cells, and in the vast majority of subjects calcitonin levels do not rise into the abnormal range following prolonged exposure to GLP-1R agonists (77).”
BackgroundSeino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Nauck, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2504 · Cited by 205
“Along the same lines, long-term treatment in obese human subjects with high liraglutide doses up to 3-mg per day does not lead to elevations in plasma calcitonin (32).”
BackgroundIepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
“A meta-analysis of sequential calcitonin measurements in over 5000 patients treated with liraglutide indicated that calcitonin levels remained low throughout the trials, which were from 26 weeks to 2 years duration [99].”
BackgroundBattle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Mabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
“However, such effects have not been observed in humans with up to 2 years treatment.(25) As such, regarding the role of calcitonin in bone biology, it is plausible that the observed anabolic effects of GLP-1 on bone in rodent models may be the result of direct effects on bone cells and indirect effects mediated via ca…”
BackgroundLinks between Thyroid Disorders and Glucose Homeostasis
Eom, Y. S., Wilson, J. R., & Bernet, V. J. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0013 · Cited by 162
“This may be due to C-cells in monkeys and humans having lower expression of GLP-1R and decreased responsiveness to GLP-1R agonists compared to rodents [125].”
BackgroundGlucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
“However, pooled data revealed that liraglutide increased plasma calcitonin levels in a dose-dependent fashion (3), but a subsequent analysis of six phase 3 clinical trials of exposure to liraglutide for 26 wk or longer in 5698 patients did not reveal any detectable change in calcitonin levels (28).”
BackgroundMadsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161
“In contrast, calcitonin increases or cellular proliferation was not seen in nonhuman primates (7), and no consistent difference between treatment groups were seen in the clinical program for liraglutide (8).”
BackgroundThe Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154
“Rodent thyroid C-cells express much higher levels of GLP-1R than primates (10, 12), and there may be an important species difference, where the GLP-1R in the rodent thyroid is important for the high bone turnover in those species but less important in humans (13, 14).”
BackgroundThe Safety of Incretin-Based Therapies—Review of the Scientific Evidence
Drucker, D. J., Sherman, S. I., Bergenstal, R. M., & Buse, J. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0599 · Cited by 151
Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., & Milicevic, Z. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12479 · Cited by 149
Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 165
“However, clinical studies have not found any indicators of elevated calcitonin levels in plasma nor thyroid cancer following prolonged treatment with GLP-1R agonists [88].”
BackgroundThe effect of glucagon-like peptide 1 on cardiovascular risk
Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 158
Do GLP-1–Based Therapies Increase Cancer Risk?
Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145
“8 mg daily (patients with type 2 diabetes) with no systematic change in calcitonin concentrations indicating any measurable response to GLP-1 receptor stimulation (34).”
BackgroundTargeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 158
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
“For example, liraglutide stimulation of C-cell proliferation has not been reported in a calcitonin screening study involving 5000 patients [181].”
BackgroundGLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 113
“In addition, plasma concentrations of calcitonin were not altered in over 5000 subjects in liraglutide clinical trials [111].”
BackgroundSilverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Ahmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., de Loredo, L., Tornøe, K., Boopalan, A., Nauck, M. A., & on behalf of the NN2211‐3917 Study Group (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12539 · Cited by 104
“Throughout this trial, mean levels of calcitonin remained within the normal range for both groups, consistent with a previous study of >5000 liraglutide-treated subjects in whom liraglutide had no clinically significant effect on calcitonin levels [50].”
ResultLiraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
“Furthermore, the lack of evidence of GLP-1 receptors on C-cells in humans has led to the hypothesis that the effects of GLP-1 RAs on thyroid are species specific [110].”
BackgroundLombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 147
Cao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99
Diabetes and Cancer—An AACE/ACE Consensus Statement
Handelsman, Y., LeRoith, D., Bloomgarden, Z. T., Dagogo-Jack, S. E., EINHORN, D. F., Garber, A. J., Grunberger, G., Harrell, R. M., Gagel, R. F., Lebovitz, H. E., et al. (2013) · Endocrine Practice · doi:10.4158/ep13248.cs · Cited by 105
“In phase 3 clinical trials, plasma calcitonin, a measure of C-cell hyperplasia and medullary thyroid carcinoma (MTC), did not increase in liraglutidetreated patients and remained below the upper normal ranges for men and women for the duration of the study (92-94).”
BackgroundGlycemic Management in ESRD and Earlier Stages of CKD
Williams, M. E., & Garg, R. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.049 · Cited by 101
Lind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Ahrén, B., Torffvit, O., Attvall, S., Ekelund, M., Filipsson, K., Tengmark, B.-O., et al. (2015) · BMJ · doi:10.1136/bmj.h5364 · Cited by 82
“39 Possible risks of pancreatitis and pancreas and thyroidal medullary cancer associated with incretin based treatments have been discussed, 40 41 but no causal association has been assessed and further evaluations are recommended in long term follow-up studies.”
Baxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H.-C., Su, C. T.-T., Cheng, M. C.-Y., Chang, Z. C.-J., Lai, E. C.-C., et al. (2025) · Thyroid® · doi:10.1089/thy.2024.0387 · Cited by 81
“14,15 19 In light of the con fl icting evidence and owing to increasing trends in GLP1-RA use, 20 we aimed to evaluate if GLP1-RAs used to treat type 2 diabetes are associated with an increased risk of thyroid cancer across six international sites, with a speci fi c focus on cumulative dose.”
Self-citationAn overview of the pharmacokinetics, efficacy and safety of liraglutide
Bode, B. W. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.015 · Cited by 94
“measured at 3-month intervals for up to 2 years in 5002 patients receiving liraglutide or control therapy in the LEAD program [44].”
BackgroundMethodInfluentialThe Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 78
“Moreover, extensive clinical follow-up coupled with thousands of calcitonin measurements have failed to reveal evidence for a functional GLP-1R C-cell axis or MTC in human subjects with diabetes or obesity treated for several years with longacting GLP-1R agonists (71,72).”
BackgroundBailey, T. S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.009 · Cited by 84
“Also, analysis of calcitonin in subjects during liraglutide phase 3 trials did not reveal a relationship between liraglutide therapy and plasma calcitonin.(74) Overall, the considerable differences between the biology of the GLP-1 system in rodents and people indicate that any risk of development of medullary thyroid…”
BackgroundGLP1 and cancer: friend or foe?
Vangoitsenhoven, R., Mathieu, C., & Van der Schueren, B. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0111 · Cited by 73
“Data gained from several prospective clinical studies, showed no increased calcitonin levels under therapy with GLP1 receptor agonists in patients with diabetes mellitus type 2 (Bjerre Knudsen et al. 2010, Hegedus et al. 2011).”
Diabetes mellitus and thyroid diseases
Nishi, M. (2018) · Diabetology International · doi:10.1007/s13340-018-0352-4 · Cited by 89
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
“25,26 Furthermore, a possible increase in overall thyroid cancer in GLP-1RA users has been reported in epidemiological studies 27,28 and clinical trials, 29 whereas other observational studies failed to detect either beneficial or detrimental effects of GLP-1RA on this endpoint.”
Hegedüs, L., Sherman, S. I., Tuttle, R. M., von Scholten, B. J., Rasmussen, S., Karsbøl, J. D., Daniels, G. H., & for the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1956 · Cited by 67
“In contrast, a different study showed that the calcitonin concentrations were statistically higher at weeks 26 and 52 with liraglutide compared with comparators; however, these levels were well within the normal range and, as with our analysis, showed no indication that these differences were of clinical significance…”
BackgroundResultInfluentialSelf-citationLuo, G., Liu, H., & Lu, H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12777 · Cited by 67
Bea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64
“…to a study by Boess et al., 32 the primary culture of human thyroid tissues did not exhibit any functional response to GLP-1RA, adding to the weight of evidence indicating that human thyroids have very low levels of functional GLP-1R, 5,28,31 which supports the results of our epidemiological study.”
ResultNovel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists
Mabilleau, G., Pereira, M., & Chenu, C. (2018) · Journal of Endocrinology · doi:10.1530/joe-17-0278 · Cited by 64
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
“Calcitonin concentration was in the lower end of normal range in all treatment groups and remained low throughout the trials [69].”
BackgroundA Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/924168 · Cited by 63
“Calcitonin, a hormone secreted by thyroid C cells, is regarded as an important clinical biomarker for C-cell diseases such as medullary thyroid carcinoma (MTC) and hereditary Ccell hyperplasia because of its high sensitivity and specificity [28–30].”
BackgroundPratley, R. E., Nauck, M. A., Bailey, T., Montanya, E., Filetti, S., Garber, A. J., Thomsen, A. B., Furber, S., Davies, M., & for the 1860-LIRA-DPP-4 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-2113 · Cited by 62
“In addition, during the trial, calcitonin levels remained below the upper normal limits for both sexes with both liraglutide and sitagliptin, consistent with findings from all phase 3 trials with liraglutide (31).”
ResultGurney, K., MacConell, L., Brown, C., & Han, J. (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s28387 · Cited by 61
“63 Overall, major adverse cardiovascular events were uncommon in this analysis.”
Cefalu, W. T., Buse, J. B., Del Prato, S., Home, P. D., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 61
“Similar human cell lines do not show such effects (125), and long-term high-dose GLP-1 receptor agonist treatment in type 2 diabetic or obese humans did not elicit elevations in plasma calcitonin (126).”
BackgroundOn-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice
Rosol, T. J. (2013) · Toxicologic Pathology · doi:10.1177/0192623312472402 · Cited by 61
“GLP-1R agonists have been reported to have minimal or no ability to stimulate calcitonin secretion in normal C-cells of primates and humans (Bjerre Knudsen et al. 2010; Hegedus et al. 2011; Joffe et al. 2009).”
BackgroundThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J., & McGowan, B. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 59
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
Jespersen, M. J., Knop, F. K., & Christensen, M. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.731394 · Cited by 57
“Calcitonin concentrations were in the lower end of normal range in all treatment groups and remained low [81].”
BackgroundMethodSun, H., Lu, N., Luo, X., Zhao, L., & Liu, J. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12282 · Cited by 59
“However, the stimulatory effects of GLP-1RA on calcitonin release observed in rodents were not demonstrated in human thyroid C cells(26) or in patients treated with liraglutide.(27) In addition, we did not measure the expression of other transcription factors responsible for osteoblast differentiation during different…”
BackgroundInventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
GLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
“However, these observations have not been replicated in primates or humans and are thought to be a rodent phenomenon because of the higher density of GLP-1Rs on rodent C-cells [50,51].”
BackgroundVitamin D in thyroid tumorigenesis and development
Clinckspoor, I., Verlinden, L., Mathieu, C., Bouillon, R., Verstuyf, A., & Decallonne, B. (2013) · Progress in Histochemistry and Cytochemistry · doi:10.1016/j.proghi.2013.07.001 · Cited by 60
Herrou, J., Mabilleau, G., Lecerf, J.-M., Thomas, T., Biver, E., & Paccou, J. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01150-8 · Cited by 50
“In rodents, but not in humans, GLP-1R is expressed by the C cells of the thyroid gland, and its activation stimulates calcitonin secretion [50, 51].”
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“The Novo Nordisk group [127, 134] examined a series of trials in more than 5000 humans with type 2 diabetes mellitus or nondiabetic obese individuals treated with liraglutide for up to two years.”
BackgroundR. Drab, S. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666151223093841 · Cited by 47
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S. H., & Rendell, M. S. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 46
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 49
Gurney, K., MacConell, L., Malloy, J., Zhou, M., & Kolterman, O. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s77290 · Cited by 45
“56–58 A US insurance claims database showed no significant increased risk of inpatient pancreatic or thyroid cancer between exenatide BID and metformin or glyburide.”
Mali, G., Ahuja, V., & Dubey, K. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13259 · Cited by 44
“[24] 2011 Randomized controlled trial Liraglutide Active comparators Placebo upto 2 y Calcitonin levels shifted to a higher category or above a clinically relevant cut-off value of 20 pg/mL (no difference between groups)”
BackgroundLotfy, M. A., Singh, J., Kalász, H., Tekes, K., & Adeghate, E. A. (2011) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501105010082 · Cited by 51
“[112]”
GLP-1 agonists in type 1 diabetes
Pettus, J., Hirsch, I. B., & Edelman, S. V. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.006 · Cited by 48
“For example, data from large clinical trials with Liraglutide in patients with T2D did not show elevation in calcitonin levels outside the normal range (a marker for medullary thyroid cancer) [50].”
MethodLiraglutide: A Review of Its Use in the Management of Obesity
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0408-8 · Cited by 48
“8 mg/day) stimulated calcitonin release from human C cells, including in patients with elevated calcitonin levels at baseline, after up to 2 years’ treatment, based on longitudinal data from patients with type 2 diabetes and obese subjects without type 2 diabetes participating in randomized clinical trials (n[ 5000) […”
MethodGLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
Liraglutide: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Perry, C. M. (2011) · Drugs · doi:10.2165/11208110-000000000-00000 · Cited by 45
“67%) developing clinically relevant serum calcitonin levels of >20ng/L up to 104 weeks after the start of treatment.([49]) Clinical evidence has shown a decrease in the efficacy of GLP-1 receptor agonists as a result of the induction of anti-GLP-1 receptor agonist antibodies.”
InfluentialPatoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 57
Daniels, G. H., Hegedüs, L., Marso, S. P., Nauck, M. A., Zinman, B., Bergenstal, R. M., Mann, J. F. E., Derving Karsbøl, J., Moses, A. C., Buse, J. B., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12444 · Cited by 42
“In combined data from nine studies of ≥20 weeks’ duration, including>5000 subjects with either type 2 diabetes or obesity without diabetes, there was no significant difference in the proportion of subjects with calcitonin concentrations>20 ng/l in the liraglutide versus the placebo groups [5].”
BackgroundInfluentialSelf-citationDifferentiating among incretin therapies: a multiple-target approach to type 2 diabetes
Cornell, S. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01342.x · Cited by 39
“Although long-term exposure to liraglutide in rodents has been associated with thyroid C-cell hyperplasia and tumours through a GLP-1 receptor-mediated mechanism,(89) 20 months of liraglutide treatment at more than 60 times human exposure levels did not produce C-cell hyperplasia in monkeys 89 and LEAD studies did not…”
BackgroundGlucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus: A Role in Cardiovascular Disease
Smilowitz, N. R., Donnino, R. M., & Schwartzbard, A. Z. (2014) · Circulation · doi:10.1161/circulationaha.113.006985 · Cited by 44
“Sustained liraglutide exposure promotes C-cell hyperplasia and medullary thyroid cancer in rodents, although evidence supporting an oncogenic effect in humans is lacking.(84,85) Despite FDA approval, liraglutide carries a black-box warning about the risk of thyroid C-cell tumors and is contraindicated in patients with…”
BackgroundThe Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Morales, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2508 · Cited by 39
“To monitor the risk of developing medullary thyroid carcinoma (MTC) during phase 3 trials, calcitonin, a marker of MTC, was monitored for up to 2 years.(100) No difference in mean calcitonin levels was found between participants treated with either liraglutide or placebo as monotherapy or add-on to glucose-lowering th…”
BackgroundJung, M. J., & Kwon, S. K. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.536 · Cited by 38
Liraglutide: from clinical trials to clinical practice
Gough, S. C. L. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01576.x · Cited by 38
“During the liraglutide development programme, five cases of C-cell hyperplasia were identified in patients receiving liraglutide and two in patients receiving a comparator; in all cases, thyroidectomies had been undertaken following abnormal plasma calcitonin levels [34].”
BackgroundPositioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 43
“Other concerns relate to C-cell thyroid tumors and stem from preclinical data from rodents (35) and may not be relevant to humans (36).”
BackgroundIncretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Byrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1722 · Cited by 36
“In separate clinical trials of GLP-1 receptor agonists, 2 years of liraglutide treatment and 2 years of dulaglutide treatment did not significantly increase calcitonin secretion, and overall mean serum calcitonin concentrations remained at the lower end of the normal range (13, 33).”
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
Fadini, G. P., & Rigato, M. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s37644 · Cited by 36
“The utility of calcitonin screening in liraglutide-treated patients is still debated.(53) The American Association of Clinical Endocrinology, in agreement with the US Food and Drug Administration (FDA), does not recommend monitoring of liraglutide-treated patients using serum calcitonin or thyroid ultrasound, because…”
BackgroundAnti-Diabetic Therapies and Cancer: From Bench to Bedside
Kounatidis, D. C., Vallianou, N. G., Karampela, Ι., Rebelos, E., Kouveletsou, M., Dalopoulos, V., Koufopoulos, P., Diakoumopoulou, E., Tentolouris, N., & Dalamaga, Μ. (2024) · Biomolecules · doi:10.3390/biom14111479 · Cited by 53
Safety of antidiabetes medications: An update
Bailey, C. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.125 · Cited by 33
Gut hormones: the future of obesity treatment?
McGavigan, A. K., & Murphy, K. G. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04278.x · Cited by 38
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 34
“In a metaanalysis of clinical trials lasting no more than 2 years with over 5000 patients receiving either liraglutide or control therapy, 3-month measurements of serum calcitonin showed that mean serum calcitonin concentrations were at the low end of the normal range in all treatment groups at baseline and remained l…”
BackgroundOnce weekly exenatide: efficacy, tolerability and place in therapy
Wysham, C., Grimm, M. F., & Chen, S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12084 · Cited by 32
“Furthermore, prolonged administration of liraglutide at very high doses did not produce C-cell proliferation in monkeys, while an analysis of sequential changes in calcitonin levels in over five thousand diabetic subjects did not reveal a relationship between liraglutide therapy and plasma calcitonin [55,56].”
BackgroundJalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
Scheen, A. J. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.10.007 · Cited by 31
“Fortunately, the concern of increased incidence of C-cell hyperplasia and medullary thyroid cancer with liraglutide reported in rodents has never been confirmed in humans [31] and no increase in calcitonin levels was reported in clinical trials up to 2 years [32].”
BackgroundKloos, R. T., Monroe, R. J., Traweek, S. T., et al. (2016) · Thyroid · doi:10.1089/thy.2016.0001 · Cited by 28
Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 32
Thyroid safety in patients treated with liraglutide
Gallo, M. (2013) · Journal of Endocrinological Investigation · doi:10.1007/bf03346749 · Cited by 27
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 30
The Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume
Sencar, M. E., Sakız, D., Çalapkulu, M., Hepşen, S., Kızılgül, M., Ozturk, U. İ., Uçan, B., Bayram, M., Cagir, B. B., Akın, Ş., et al. (2019) · European Thyroid Journal · doi:10.1159/000501895 · Cited by 38
Current Long-Term Pharmacotherapies for the Management of Obesity
Kim, B.-Y., Kang, S. M., Kang, J., Kim, K. K., Kim, B., Kim, S. J., Kim, Y., Kim, J. H., Kim, J. H., Nam, G. E., et al. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20010 · Cited by 29
Metadata
- Authors
- Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H.
- Affiliations
- Department of Endocrinology (L.H.), Odense University Hospital, 5000 Odense, Denmark;
- Novo Nordisk Inc. (A.C.M.), Princeton, New Jersey 08540;
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S (M.Z., T.L.T.), 2880 Bagsværd, Denmark;
- Harvard University (US)
- ORCID
- Daniels, Gilbert H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-03-01
- Volume
- 96
- Issue
- 3
- Pages
- 853-860
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118710260
- Cited by
- 194
- References
- 25
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 8 · 2023: 9 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 14 · 2018: 7 · 2017: 7 · 2016: 10 · 2015: 26 · 2014: 19 · 2013: 28 · 2012: 29
- FWCI
- 23.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Funders
- Novo Nordisk
- Odense Universitetshospital
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- calcitonin, liraglutide, GLP-1 receptor agonists, type 2 diabetes, obesity, medullary thyroid carcinoma, long-term safety, rodent-to-human extrapolation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Adult, Calcitonin, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Receptors, Glucagon, Diabetes Complications, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.